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Science  deserves  justice:  The  results  of  the CABANA
trial are  positive  and support  catheter  ablation  of atrial
ﬁbrillation for reducing  mortality  and  hospitalizations
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A positive study
Despite  mxed  reactions  among  the  cardiovascular  com-
munity,  the  recently  published  Catheter  ABlation  vs
ANtiarrhythmic  Drug  Therapy  in  Atrial  Fibrillation  (CABANA)
trial  should  be  considered  positive,  as  it  provides  clear
evidence  that  catheter  ablation  is  a  valuable  option  for
treating  patients  with  atrial  ﬁbrillation  (AF).  In  CABANA,
not  only  did  catheter  ablation  reduce  the  AF  burden  and
prolong  time  to  ﬁrst  recurrence,1 but  it  also  improved
quality  of  life.2 Furthermore,  and  most  importantly,  it
reduced  all-cause  mortality  and  cardiovascular  hospital-
izations  (HR  0.83,  95%  CI  0.74-0.93,  p=0.001).1 What  this
means  is  that  for  every  15.6  patients  randomized  to  catheter
ablation,  one  death  or  cardiovascular  hospitalization  was
prevented  (number  needed  to  treat  [NNT]  15.6).  This  is  an
extremely  informative  and  powerful  endpoint,  as  it  is  used
for  showing  the  beneﬁt  of  most  interventions  across  the
spectrum  of  cardiovascular  disease  (Figure  1).  The  fact  that
it  is  a  secondary  endpoint  in  CABANA  does  not  reduce  its
importance.Please  cite  this  article  in  press  as:  Providencia  R,  Adragão  P.  Sci
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The  patient  subgroup  that  derived  most  beneﬁt  from
atheter  ablation  was  younger  individuals  (less  than  65  years
ld).1 This  result  is  not  surprising  considering  that  most  of
hese  patients  live  long  enough  to  experience  a  mortality
eneﬁt  from  the  intervention.
In  CABANA,  no  atrio-esophageal  ﬁstulas,  stroke  or
rocedure-related  mortality  were  observed.  Procedure-
ssociated  complications  included  myocardial  infarction  in
1/1000,  need  for  pericardiocentesis  in  0.8%,  and  vascular
ccess  complications  in  3.9%.  At  the  same  time,  ventricu-
ar  tachycardia  or  ventricular  ﬁbrillation  was  observed  in
.8%,  and  thyroid  dysfunction  in  1.6%,  in  the  medical  treat-
ent  arm.  This  eases  some  of  the  concerns  associated  with
blation3 and  illustrates  that  being  assigned  to  antiarrhyth-
ic  agents  is  also  not  devoid  of  risk.
ssues with study design and arising during the
rial
.  Nearly  a  third  of  patients  initially  randomized  to  treat-
ent  with  antiarrhythmic  agents  were  later  treated  withence  deserves  justice:  The  results  of  the  CABANA  trial  are
reducing  mortality  and  hospitalizations.  Rev  Port  Cardiol.
blation.  On  the  other  hand,  almost  10%  of  patients  ran-
omized  to  catheter  ablation  did  not  receive  this  treatment.
hese  are  excessively  high  cross-over  rates,  and  are  unequal
n  the  two  treatment  arms.
ciedade Portuguesa de Cardiologia. This is an open access article
y-nc-nd/4.0/).
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Figure  1  Clinical  events  in  some  of  the  main  cardiovascular
trials. (A)  and  (B)  show  the  number  of  patients  who  need  to
be treated  for  a  fatal  event  to  be  prevented  (A),  or  for  a
fatal event  or  hospitalization  to  be  avoided  (B).  We  chose  to
include  trials  of  different  cardiovascular  interventions  that
have demonstrated  signiﬁcant  beneﬁt  in  the  prevention  of
these events.  Interpretation  of  these  graphs  shows  that  among
all these  interventions  whose  beneﬁt  has  been  demonstrated
in landmark  trials,  and  most  of  which  have  led  to  indications
in the  guidelines,  the  interventions  with  more  beneﬁt,  as  rep-
resented  by  a  larger  number  of  lives  saved  or  hospitalizations
avoided,  are  those  with  a  smaller  number  needed  to  treat  to
prevent  one  event.  As  such,  interventions  with  most  beneﬁt  as
measured  by  the  number  needed  to  treat  are  those  which  are
located  closer  to  the  origin  on  the  x  axis.  Furthermore,  in  (A)
the results  of  CABANA  are  highlighted  in  red  for  two  different
reasons:  ﬁrst,  inclusion  of  the  results  of  the  as-treated  analysis,
with  an  NNT  of  32.3,  and  secondly,  inclusion  of  the  results
of the  ITT  analysis,  which  were  not  signiﬁcant  due  to  the
small sample  size.  However,  CABANA  shows  a  larger,  albeit
non-signiﬁcant,  impact  than  the  novel  oral  anticoagulants
and statins  in  some  populations.  Randomized  trials  for:  AF  --
CASTLE-AF  and  CABANA;  cardiac  resynchronization  therapy
-- CARE-HF  and  COMPANION;  beta-blockers  --  COPERNICUS;
angiotensin-converting  enzyme  inhibitors  --  SOLVD;  PARADIGM-
HF --  valsartan  +  sacubitril  vs.  enalapril;  statins  and  treatment
of dyslipidemia  --  HPS,  JUPITER  and  IMPROVE-IT;  anti-platelet
agents  --  CURE,  PLATO  and  TIMI-38  TRITON;  anti-arrhythmic
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2.  There  were  weaknesses  in  the  selection  and  deﬁ-
ition  of  the  trial’s  primary  endpoint.  This  was  changed
uring  the  course  of  CABANA,  from  all-cause  mortality  to
 combined  endpoint  of  all-cause  mortality,  incapacitating
troke,  major  bleed  or  cardiac  arrest.  Why  did  the  inves-
igators  not  choose  a  more  widely  accepted  endpoint,  like
ll-cause  mortality  and  hospitalizations?  A  recent  trial  com-
aring  transcatheter  aortic  valve  replacement  and  surgical
ortic  valve  replacement  in  low  surgical  risk  patients  has
een  hailed  as  a  success,  as  the  newer  treatment  reduced
he  rate  of  the  composite  of  death,  stroke,  or  rehospital-
zation  at  one  year.4 Would  not  the  same  apply  to  CABANA
f  it  had  used  a  similar  primary  endpoint?  It  should  be
ecalled  that  the  intention-to-treat  (ITT)  analysis  showed
hat  catheter  ablation  signiﬁcantly  reduced  mortality  and
ospitalizations,  and  the  rate  of  stroke  in  the  catheter  abla-
ion  arm  was  numerically  50%  lower,  which  leads  one  to
uspect  that  such  an  endpoint  would  also  very  likely  show  a
igniﬁcant  difference.
It  is  interesting  to  note  that  the  combined  primary  end-
oint  in  CABANA  included  events  like  stroke  and  bleeding,
s  well  as  mortality  and  cardiac  arrest.  Ablation  was  numer-
cally  better  for  all  of  them  except  bleeding,  for  which  the
vent  rate  was  the  same  (as  would  be  expected  as  patients
n  both  treatment  arms  were  on  anticoagulants).
3.  Patients  who  had  previously  not  tolerated  or  had
elapsed  on  more  than  two  antiarrhythmic  drugs,  or  were
n  full-dose  amiodarone,  were  not  included  in  the  study.
ABANA  therefore  excluded  a  good  percentage  of  real-world
F  patients  currently  being  referred  for  ablation.
4.  To  be  included  in  CABANA,  patients  had  to  be  eligible
or  catheter  ablation.5 However,  some  patients  who  were
ncluded  in  the  study  and  randomized  to  ablation  ended  up
ot  having  the  procedure.  In  the  lead  author’s  own  words,
‘the  main  reason  for  that  is  that  patients  changed  their
inds,  or  a  physician  changed  their  mind  for  them.  Or  if  you
o  to  China  or  Korea,  there  are  other  conditions  that  are
mportant  there.’’  With  regard  to  this  point,  the  Medscape
ditor  responsible  for  the  article  added:  ‘‘In  Packer’s  HRS
resentation,  he  said  of  these  countries  that  often  ‘if  you
on’t  go  into  the  hospital  with  a  bag  of  money,  you  will  not
et  ablated.’’’6 Box  III  in  CABANA  appears  to  conﬁrm  this
y  showing  that  patients  randomized  to  the  ablation  arm
ut  not  receiving  ablation  were  more  frequently  from  ethnic
inorities.1 This  raises  several  questions  regarding  the  eligi-
ility  of  these  patients  and  the  trial’s  organization.  If  money
as  required  for  patients  to  have  an  ablation  procedure  and
hey  were  unable  to  pay,  should  they  have  been  considered
ligible  for  the  trial  in  the  ﬁrst  place?  Should  centers  that
ehaved  in  this  way  toward  clinical  trial  patients  have  been
llowed  in  the  trial?  In  mega-drug  trials,  the  sponsor  pro-ience  deserves  justice:  The  results  of  the  CABANA  trial  are
reducing  mortality  and  hospitalizations.  Rev  Port  Cardiol.
ides  the  drug  free  of  charge.  Could  CABANA  not  have  done
he  same  with  the  ablation  treatment  for  these  patients?
gents  --  ATHENA;  anticoagulants  --  ARISTOTLE.  CV:  cardiovas-
ular; CRT:  cardiac  resynchronization  therapy;  CRT-D:  cardiac
esynchronization  therapy-deﬁbrillator;  HF:  heart  failure;  MI:
yocardial  infarction;  OPT:  optimal  pharmacologic  therapy.
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Science  deserves  justice:  The  results  of  the  CABANA  trial  
Beneﬁt of catheter ablation for heart failure
patients
CABANA  included  AF  patients  with  and  without  heart  fail-
ure.  The  ITT  sub-analysis  of  the  primary  endpoint  for  heart
failure  patients  suggests  a  beneﬁt  of  ablation,  with  a  39%
risk  reduction,  which  nearly  crosses  the  boundary  of  signif-
icance.  This  was  despite  there  being  only  1197  patients  in
the  study  with  heart  failure.1
The  CASTLE-AF  trial  suggested  a  clear  beneﬁt  of  this
treatment  modality  in  the  subgroup  of  patients  with  AF  and
heart  failure  and  left  ventricular  dysfunction.7 The  NNT  to
save  a  life  was  8.6,  and  to  prevent  one  heart  failure  hos-
pitalization  it  was  6.6.  These  results  are  therefore  in  line
with  the  trend  observed  in  CABANA,  and  with  recently  pub-
lished  systematic  reviews  of  randomized  trials  that  showed
a  similar  reduction  in  mortality  and  effect  size  with  catheter
ablation  in  the  AF  population.  This  effect  became  morePlease  cite  this  article  in  press  as:  Providencia  R,  Adragão  P.  Sci
positive  and  support  catheter  ablation  of  atrial  ﬁbrillation  for  
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pronounced  in  sub-analyses  of  studies  including  only  heart
failure  patients.8,9
Several  factors  have  been  suggested  to  explain  the  ben-
eﬁt  of  AF  ablation  in  patients  with  heart  failure,  which  are
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h
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Table  1  Levels  of  evidence  for  the  impact  of  atrial  ﬁbrillation  rh
Catheter  ablation  
Level  of  evidence  A
Data  derived  from  multiple
RCTs  or  meta-analyses
Mortality  
RCTs 
CASTLE-AF7 a 46%b
AATAC17 a 56%b
Meta-analyses  
Barra  et  al.8 55%b
Turagam  et  al.9  a 48%
Hospitalizations
RCTs
CASTLE-AF7  a 50%b
AATAC17  a 45%b
Meta-analyses
Turagam  et  al.9  a 40%
Mortality  and  hospita
RCTs
CABANA1 17%b
CASTLE-AF7 a 38%b
Level  of  evidence  B
Data  derived  from  a  single
RCT  or  large
non-randomized  studies
Mortality
Large  non-RCTs
Friberg  et  al.21 50%b
a Studies including only heart failure patients.
b RCTs including only >100 patients.
RCT: randomized controlled trial. The percentage changes shown are r PRESS
3
iscussed  in  more  detail  by  Kadhim  et  al.10 Statistical  con-
iderations  concerning  this  subject  are  discussed  in  Box  II.
ffect size of catheter ablation on hard
utcomes
igure  1  shows  the  effect  size,  represented  by  the  NNT,
f  several  drugs  and  interventions  currently  used  in  car-
iovascular  medicine  and  recommended  in  international
uidelines.  It  is  interesting  to  note  that  the  effect  size  and
eneﬁt  for  some  of  these  drugs  appear  to  be  much  lower
han  that  observed  with  catheter  ablation  (Figure  1A  and
).  Using  apixaban,  one  of  the  novel  oral  anticoagulants,
nstead  of  a  vitamin  K  antagonist,  we  would  need  to  treat
32  AF  patients  to  save  one  life,11 while  in  the  population
ith  heart  failure  in  PARADIGM-HF,  the  association  of  val-
artan  and  sacubitril  needs  to  be  used  instead  of  enalapril
n  37.8  and  35.7  patients  to  save  one  life  or  prevent  oneence  deserves  justice:  The  results  of  the  CABANA  trial  are
reducing  mortality  and  hospitalizations.  Rev  Port  Cardiol.
eart  failure  hospitalization,  respectively.12 This  is  also  seen
ith  drugs  whose  use  is  considered  unquestionable  in  coro-
ary  artery  disease,  like  ticagrelor  instead  of  clopidogrel,
ythm  control  strategies  on  mortality  and  hospitalizations.
Antiarrhythmic  drugs
Mortality
RCTs
PALLAS18 111%b dronedarone
Meta-analyses
Lafuente-Lafuente  et  al.19
123%b sotalol
b 139%b quinidine  and  disopyramide
Freemantle  et  al.20
173%b amiodaroneb
332%b sotalol b
b
lizations
Hospitalizations
RCTs
PALLAS18 81%b Dronedarone
ATHENA22 26%b Dronedarone
Mortality  and  hospitalizations
RCTs
ATHENA22 24%b Dronedarone
elative.
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appears  to  have  been  the  case  in  CABANA.  ITT  anal-
yses  are  usually  considered  to  be  more  conservative
(except  for  situations  when  the  reference  treat-
ment  is  more  effective  than  the  new  treatment,
which  is  clearly  not  the  case  with  ablation).  Also,
ITT  analyses  provide  information  on  the  average
causal  effect  of  being  assigned  a  treatment.  A  dif-
ferent  type  of  analysis  should  be  adopted  if  one
wants  to  know  the  actual  average  causal  effect  of
receiving  a treatment.23 In  our  view,  the  ITT  anal-
ysis  shows  what  happens  when  planned  ablation  at
randomization  is  compared  to  medical  therapy  and
possible  ablation  at  a  later  date.
↓  All-cause  mortality  and  cardiovascular  hospitaliza-
tion:  HR  0.83,  95%  CI  0.74-0.93,  p=0.001,  NNT  15.6
b)  As-treated  (treatment  received):  This  analysis  com-
pares  patients  who  actually  received  ablation  with
those  who  were  treated  with  antiarrhythmic  agents
only.  The  concern  with  this  analysis  is  that  it  may
remove  the  effect  of  randomizing  of  patients  into
two  equal  groups.
↓  All-cause  mortality:  HR  0.60,  95%  CI  0.42-0.86;
p=0.005,  NNT  32.3
↓  All-cause  mortality  and  cardiovascular  hospitaliza-
tion:  HR  0.83,  95%  CI,  0.74-0.94;  p=0.002,  NNT  3.0
↓  Combined  primary  endpoint:  HR  0.67,  95%  CI  0.50-
0.89,  p=0.006
c)  Per-protocol:  This  analysis  censors  patients  who
cross  over  to  a  different  treatment  from  that
assigned  at  randomization.  In  the  drug  treatment
group,  follow-up  of  patients  who  received  drug
therapy  and  crossed  over  to  catheter  ablation  was
censored  at  the  time  of  ablation.  The  per-protocol
catheter  ablation  group  included  patients  random-
ized  to  catheter  ablation  who  received  ablation
within  a  pre-speciﬁed  time  window.  Results  for
patients  who  received  ablation  in  the  ﬁrst  three
months  are  shown  below  (similar  results  were
observed  for  those  receiving  ablation  within  six  and
12  months;  however,  it  should  be  borne  in  mind  that
some  patients  were  randomized  to  ablation  and  had
to  wait  for  months  before  having  the  procedure,  and
during  that  period  (sometimes  over  six  months)  they
were  already  in  the  ablation  arm  of  the  study).
↓ All-cause  mortality:  HR  0.68,  95%  CI  0.47-0.99,
p=0.047
↓  Combined  primary  endpoint:  HR  0.73,  95%  CI  0.54-
0.99,  p=0.046
Note:  The  NNT  could  only  be  estimated  when  the
percentage  of  events  was  available.ARTICLEEPC-1382; No. of Pages 6
 
or  which  the  number  of  patients  needed  to  treat  to  prevent
ne  fatal  event  is  71.4.13
Even  the  most  conservative  analysis  of  CABANA  (the  ITT
nalysis  ‘‘shows  a  clear  signiﬁcant  reduction’’)  of  the  all-
ause  mortality  and  cardiovascular  hospitalization  endpoint
HR  0.83,  95%  CI  0.74-0.93,  p=0.001),  which  translates  into
n  NNT  of  15.6.1
he  question  of  ablation  timing  and  level  of
vidence in  the  guidelines
re  the  data  sufﬁcient  to  support  a  strategy  of  early  AF  abla-
ion  --  the  earlier  the  better?  Knowledge  of  predictors  of
uccess  for  this  procedure,  like  AF  episode  duration  and  left
trial  size,  and  the  fact  that  ‘AF  begets  AF’  and  that  younger
atients  derive  more  beneﬁt,  appear  increasingly  to  support
uch  a  strategy.14,15
As  a  matter  of  coherence,  it  cannot  be  much  longer
efore  the  next  AF  guideline  updates  include  a  clear  rec-
mmendation  for  this  procedure  with  the  aim  of  improving
urvival  in  patients  with  heart  failure  and  LV  systolic  dysfunc-
ion  (class  of  recommendation  I,  level  of  evidence  A),  and
xpand  the  current  class  I,  level  of  evidence  A  indication
ffering  catheter  ablation  to  patients  with  paroxysmal  AF
nd  recurrent  AF  while  on  antiarrhythmic  agents,  to  include
atients  with  persistent  AF  (as  these  represent  the  majority
f  patients  in  the  CABANA  and  CASTLE-AF  trials).  Table  1  pro-
ides  some  information  on  the  available  evidence  and  how
his  is  incorporated  in  the  current  European  and  American
lassiﬁcation  of  level  of  evidence.  At  this  point,  the  need  for
 randomized  controlled  trial  comparing  catheter  ablation
nd  a  sham  procedure,  as  previously  conducted  for  percu-
aneous  coronary  intervention  in  stable  angina,16 is  highly
ebatable.
ake-home  messages  of  CABANA
he  main  messages  of  this  positive  study,  which  conﬁrms
he  beneﬁt  of  catheter  ablation  of  AF  on  hard  outcomes,
re  highlighted  in  Box  III.
Box  I.  The  CABANA  trial:  types  of  analysis  and  impact
on  hard  outcomes
a)  Intention-to-treat  (ITT):  This  analysis  compares
patients  based  exclusively  on  the  treatment
assigned  at  randomization.  This  is  the  method  pre-
ferred  by  methodologists  and  was  the  planned
analysis  for  CABANA  right  from  the  start.  How-
ever,  it  is  important  to  note  that  102  patients
(9.2%)  randomized  for  ablation  in  CABANA  did  not
receive  this  treatment,  and  301  patients  (27.5%)
randomized  for  medical  therapy  ended  up  receiving
ablation,  but  in  the  ITT  analysis  they  appear  in  the
ablation  and  medical  therapy  arms,  respectively.
Interestingly,  ITT  analyses  are  discouraged  when
23Please  cite  this  article  in  press  as:  Providencia  R,  Adragão  P.  Sc
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Box  II.  Catheter  ablation  trials:  considerations  of
effect  size,  power  and  sample  size
It  has  been  clearly  demonstrated  that  to  show  a
similar  reduction  in  relative  risk  (e.g.  30%)  in  two  pop-
ulations  with  different  baseline  absolute  risks  (e.g.  1%
in  population  A  and  20%  in  population  B),  the  popu-
lation  with  lower  risk  at  baseline  would  need  a  much
larger  sample  (29  396  patients  for  the  population  with
1%  risk  at  baseline  vs.  1228  patients  for  the  population
with  20%  risk  at  baseline,  assuming  a  1:1  randomiza-
tion,  and    of  0.05  and    of  0.8).  Accordingly,  it  is  not
surprising  that  a  clear  beneﬁt  of  catheter  ablation  was
shown  for  patients  with  heart  failure  in  CABANA,  given
their  higher  baseline  risk  for  hospitalization  or  all-cause
mortality  (and  thus  requiring  a  smaller  sample).
On  the  other  hand,  showing  a  signiﬁcant  reduction
in  stroke  may  be  a  more  difﬁcult  task.  In  a  world  where,
unlike  in  AFFIRM24 or  RACE,25 nearly  all  AF  patients  are
anticoagulated,  the  incidence  of  stroke  is  now  very  low
(about  1.25%  annually  in  the  ENGAGE  AF-TIMI  48  trial
among  patients  treated  with  vitamin  K  antagonists  or
edoxaban  60  mg  daily).26 Using  the  ﬁgures  from  the
previous  example  (starting  from  a  baseline  absolute  risk
of  1.25%,  and  aiming  for  a  30%  relative  risk  reduction,
with  1:1  randomization  and  =0.05  and  =0.8),  it  would
be  necessary  for  a  randomized  trial  to  include  at  least
23  466  participants  to  show  such  a  protective  effect.
This  study  population  would  be  about  10  times  the  size
of  CABANA  (which  included  only  2204  patients).
Besides,  as  AF  patients  have  multiple  other  cardio-
vascular  risk  factors  (including  hypertension,  diabetes,
obesity,  sleep  apnea,  etc),  the  treatment  of  an  atrial
myopathy  will  not  by  itself  protect  them  from  all  the
associated  stroke  and  cardiovascular  risk  factors.
Box  III.  CABANA  trial:  summary,  assessment  and
take-home  messages
1.  Patients  who  received  ablation  had  lower  mortality
and  cardiovascular  hospitalization  rates.
2.  Mortality  reduction  with  ablation  may  be  observed
in  higher  risk  patients  (heart  failure  population).
3.  The  results  were  positive  for  younger  patients,  who
are  likely  to  live  long  enough  to  suffer  the  deleteri-
ous  effects  of  AF.
4.  The  severity  of  complications  and  side  effects  of
ablation  was  comparable  to  the  severity  of  antiar-
rhythmic  complications  in  the  medical  treatment
arm.
5.  Ablation  reduced  the  total  AF  burden  and  prolonged
the  time  to  ﬁrst  AF  relapse.
6.  Peculiar  study  design:
a.  unusual  and  surprising  choice  of  combined  end-
point,  which  was  used  for  the  ﬁrst  (and  likely
only)  time  in  this  trial;
b.  slow  patient  recruitment  due  to  unusual  inclu-
sion  criteria;
c. protracted  study  even  after  modiﬁcation  of  the
primary  endpoint  when  the  study  was  ongoing;
this  occurred  due  to  the  lower  than  expected
number  of  events,  and  issues  with  estimation  of
required  sample  size.
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